Megakaryocytic growth in patients with refractory anemia is suppressed by treatment with interferon alpha

European Journal of Haematology

Volumn 62, Issue 5, 1999, Pages 336-340

  Hofmann, Wolf Karsten ^a   Kalina, Uwe ^a   Seipelt, Gernot ^a   Hoffmann, Kristina ^b   Wagner, Sandra ^a   Hoelzer, Dieter ^a   Ottmann, Oliver G ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Interferon alpha; Megakaryocytes; Myelodysplastic syndrome; PEG rHuMGDF

Indexed keywords

ALPHA INTERFERON; RETINOIC ACID;

ADULT; AGED; ARTICLE; CELL COUNT; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOTHERAPY; MALE; MEGAKARYOPOIESIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REFRACTORY ANEMIA; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032951911     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1999.tb01912.x     Document Type: Article

References (24)

1. Hofmann WK, Ottmann OG, Ganser A, Hoelzer D. Myelodysplastic syndromes: clinical features. Semin Hematol 1996;33:177-185.
2. Seipelt G, Ganser A, Duranceyk H, Maurer A, Ottmann OG, Hoelzer D. Induction of TNF-alpha in patients with myelodysplastic syndromes undergoing treatment with interleukin-3. Br J Haematol 1993;84:749-751.
3. Volkers B, Ganser A, Greher J, Stella CC, Hoelzer D. Effect of tumor necrosis factor on human hematopoietic precursor cells. Onkologie 1989;12:109-115.
4. Parker JE, Mufti GJ. Ineffective haemopoiesis and apoptosis in myelodysplastic syndromes. Br J Haematol 1998;101:220-230.
5. Gallagher RE, Lurif KJ, Leavitt RD, Wiernik PH. Effects of interferon and retinoic acid on the growth and differentiation of clonogenic leukemic cells from acute myelogenous leukemia patients treated with recombinant leukocyte-alpha A interferon. Leuk Res 1987;11:609-619.
6. Elias L, Hoffman R, Boswell S, Tensen L, Bonnem EM. A trial of recombinant alpha 2 interferon in the myelodysplastic syndromes: I. Clinical results. Leukemia 1987;1:105-110.
7. Nand S, Ellis T, Messmore H, Fisher SG, Gaynor E, Fisher RI. Phase II trial of recombinant human interferon alpha in myelodysplastic syndromes. Leukemia 1992;6:220-223.
8. Holcombe RF. Mini-dose interferon alpha-2a in the treatment of myelodysplasia. Leukemia 1993;7:192-195.
9. Gisslenger H, Chott A, Linkesch W, Fritz E, Ludwig H. Long-term alpha-interferon therapy in myelodysplastic syndromes. Leukemia 1990;4:91-94.
10. Petti MC, Latagliata R, Avvisati G, et al. Treatment of high-risk myelodysplastic syndromes with lymphoblastoid alpha interferon. Br J Haematol 1996;95:364-367.
11. Aul C, Gattermann N, Schneider W. Treatment of advanced myelodysplastic syndromes with recombinant interferon-alpha 2b. Eur J Haematol 1991;46:11-16.
12. Ohno R, Naoe T, Hirano M, et al. Treatment of myelodysplastic syndromes with all-trans retinoic acid. Leukemia Study Group of the Ministry of Health and Welfare. Blood 1993;81:1152-1154.
13. Hellstrom E, Robert KH, Gahrton G, et al. Therapeutic effects of low-dose cytosine arabinoside, alpha-interferon, 1 alpha-hydroxyvitamin D3 and retinoic acid in acute leukemia and myelodysplastic syndromes. Eur J Haematol 1988;40:449-459.
14. Hofmann WK, Ganser A, Ottmann OG, et al. All-trans retinoic acid (ATRA), interferon alpha (IFNα), and granulocyte colony-stimulating factor (G-CSF) as combination therapy in patients with low-risk myelodysplastic syndromes (MDS). Blood 1997;90(S1):84a.
15. Ganser A, Seipelt G, Verbeek W, et al. Effect of combination therapy with all-trans-retinoic acid and recombinant human granulocyte colony-stimulating factor in patients with myelodysplastic syndromes. Leukemia 1994;8:369-375.
16. Ganser A, Maurer A, Contzen C, et al. Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all-trans-retinoic acid, granulocyte colony-stimulating factor, erythropoietin and alpha-tocopherol. Ann Hematol 1996;72:237-244.
17. Ganser A, Carlo-Stella C, Greher J, Volkers B, Hoelzer D. Effect of recombinant interferons alpha and gamma on human bone marrow-derived megakaryocytic progenitor cells. Blood 1987;70:1173-1179.
18. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-199.
19. Morosetti R, Koeffler HP. Differentiation therapy in myelodysplastic syndromes. Semin Hematol 1996; 33:236-245.
20. Hunt P, Li YS, Nichol JL, et al. Purification and biologic characterization of plasma-derived megakaryocyte growth and development factor. Blood 1995;86:540-547.
21. Adams JA, Lui Yin JA, Brereton ML, Briggs M, Burgess R, Hyde K. The in vitro effect of pegylated recombinant human megakaryocyte growth and development factor (PEG rHuMGDF) on megakaryopoiesis in normal subjects and patients with myelodysplasia and acute myeloid leukaemia. Br J Haematol 1997; 99:139-146.
22. Hofmann WK, Kalina U, Wagner S, et al. Characterization of defective megakaryocytic development in patients with myelodysplastic syndromes. Exp Hematol (in press).
23. Tiefenbrun N, Melamed D, Levy N, et al. Alpha interferon suppresses the cyclin D3 and cdc25A genes, leading to a reversible G0-like arrest. Mol Cell Biol 1996;16:3934-3944.
24. Aman MJ, Keller U, Derigs G, Mohamadzadeh M, Huber C, Peschel C. Regulation of cytokine expression by interferon-alpha in human bone marrow stromal cells: inhibition of hematopoietic growth factors and induction of interleukin-1 receptor antagonist. Blood 1994;84:4142-4150.